Immunoconjugates
Showing 1 - 25 of 113
Cancer Trial (Antibody-Drug Conjugate)
Not yet recruiting
- Cancer
- Antibody-Drug Conjugate
- (no location specified)
Aug 23, 2023
Acute Lymphoblastic Leukemia Treated With Anti-CD22
Recruiting
- Acute Lymphoblastic Leukemia
- Anti-CD22 Immunotoxin
-
Meldola (FC), FC, Italy
- +4 more
Feb 25, 2021
Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8 Trial in Seattle
Recruiting
- Muscle Invasive Bladder Carcinoma
- +2 more
- Lymphadenectomy
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 9, 2023
Renal Pelvis and Ureter Urothelial Carcinoma Trial in Los Angeles (procedure, drug, biological)
Not yet recruiting
- Renal Pelvis and Ureter Urothelial Carcinoma
- Biopsy
- +5 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Mar 15, 2023
Advanced Solid Tumor Trial in New York (STI-6129)
Not yet recruiting
- Advanced Solid Tumor
- STI-6129
-
New York, New YorkColumbia University Medical Center
Jan 26, 2023
Relapsed Solid Tumor, Refractory Cancer, Solid Tumor, Adult Trial (STI-3258)
Withdrawn
- Relapsed Solid Neoplasm
- +2 more
- STI-3258
- (no location specified)
Jan 24, 2023
Light Chain (AL) Amyloidosis Trial (STI-6129)
Not yet recruiting
- Light Chain (AL) Amyloidosis
- STI-6129
- (no location specified)
Jan 11, 2023
Metastatic Penile Squamous Cell Carcinoma, Stage III Penile Cancer AJCC v8, Stage IV Penile Cancer AJCC v8 Trial in Phoenix,
Not yet recruiting
- Metastatic Penile Squamous Cell Carcinoma
- +3 more
- Enfortumab Vedotin
-
Phoenix, Arizona
- +2 more
Oct 23, 2023
Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Seattle (drug, other,
Recruiting
- Recurrent Hodgkin Lymphoma
- +3 more
- Brentuximab Vedotin
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 4, 2022
Advanced and Metastatic Solid Tumor Trial in Shanghai (FZ-AD004)
Not yet recruiting
- Advanced and Metastatic Solid Tumor
-
Shanghai, ChinaShanghai Chest Hospital
Jun 13, 2023
Advanced Solid Tumors Trial (FDA022 Monoclonal antibody-drug conjugate for injection)
Not yet recruiting
- Advanced Solid Tumors
- FDA022 Monoclonal antibody-drug conjugate for injection
- (no location specified)
Sep 29, 2022
Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate
Recruiting
- Aggressive Non-Hodgkin Lymphoma
- +8 more
- Polatuzumab Vedotin
- +6 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 26, 2023
Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Tumor Trial in Atlanta (procedure,
Not yet recruiting
- Bladder Squamous Cell Carcinoma
- +10 more
- Biospecimen Collection
- +5 more
-
Atlanta, Georgia
- +3 more
Feb 20, 2023
Light Chain (AL) Amyloidosis Trial in New York (STI-6129)
Recruiting
- Light Chain (AL) Amyloidosis
- STI-6129
-
Duarte, California
- +3 more
Jan 12, 2023
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Tumor in the Brain Trial in Duarte
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +2 more
- Copper Cu 64-DOTA-Trastuzumab
- +4 more
-
Duarte, CaliforniaCity of Hope Medical Center
Nov 22, 2022
Reporting of Antibody-Drug Conjugate Associated Sepsis-related
Completed
- Sepsis (SMQ)
- +2 more
- Antibody-Drug Conjugate
- Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate
-
Changsha, Hunan, ChinaCentral South University
Jun 19, 2022
Acute Myeloid Leukemia, Myeloid Tumor Trial in Seattle (Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy)
Not yet recruiting
- Acute Myeloid Leukemia
- Myeloid Neoplasm
- Biospecimen Collection
- +9 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Sep 5, 2023
DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to DLBCL Trial
Not yet recruiting
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- +2 more
- Biospecimen Collection
- +5 more
- (no location specified)
Sep 5, 2023
Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer Trial in United States (IMMU-130)
Withdrawn
- Metastatic Colorectal Cancer
- +2 more
-
Santa Monica, California
- +6 more
Aug 12, 2021
Osteosarcoma, Recurrent Osteosarcoma Trial in United States (Trastuzumab Deruxtecan)
Suspended
- Osteosarcoma
- Recurrent Osteosarcoma
- Trastuzumab Deruxtecan
-
Birmingham, Alabama
- +27 more
Oct 21, 2022
HER2-Positive Breast Carcinoma, Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor Trial in United States
Recruiting
- Advanced Malignant Solid Neoplasm
- +4 more
- Biopsy
- +3 more
-
Bethesda, Maryland
- +4 more
Jan 21, 2023
Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell
Recruiting
- Recurrent Angioimmunoblastic T-Cell Lymphoma
- +13 more
- Brentuximab Vedotin
- Pembrolizumab
-
Chicago, IllinoisNorthwestern University
Jun 15, 2022
Breast Tumors Trial in Shenyang (Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting
Recruiting
- Breast Neoplasms
- Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788)
-
Shenyang, Liaoning, ChinaShengjing Hospital affiliated to China Medical University
Jul 30, 2022
Metastatic Colorectal Cancer Trial (IMMU 130)
Withdrawn
- Metastatic Colorectal Cancer
- IMMU 130
- (no location specified)
Aug 12, 2021
Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma, Metastatic
Recruiting
- Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation
- +3 more
- Cabozantinib S-malate
- +3 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Aug 8, 2022